The sequential development of tissue-specific insulin resistance and metabolic disruptions, rather than simultaneous whole-body desensitization to insulin, serves as the preferential pathological background for type 2 diabetes [1]. This evidence concerns the gene INS and type 2 diabetes mellitus.